- Conditions
- Multiple Myeloma
- Interventions
- CCI-779, Bortezomib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis B
- Interventions
- AHB-137 injection, Placebo
- Drug
- Lead sponsor
- AusperBio Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Redwood City, California • Baltimore, Maryland • New York, New York + 1 more
- Conditions
- Multiple Sclerosis, Diet, Healthy
- Interventions
- Time Restricted Feeding
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Urinary Incontinence
- Interventions
- Multi-modal rehabilitation program, Pelvic Floor Physical therapy
- Other
- Lead sponsor
- Howard University
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diagnostic Imaging, Neoplasms
- Interventions
- BAY94-9392
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
- Interventions
- Tovaxin
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 27
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Rocky Mountain MS Research Group, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Keratoconus, Corneal Ectasia
- Interventions
- KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution
- Device · Drug
- Lead sponsor
- American-European Congress of Ophthalmic Surgery
- Network
- Eligibility
- 12 Years and older
- Enrollment
- 1,721 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation
- Drug · Biological · Other + 2 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
- Interventions
- Tcelna, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
- Conditions
- X-linked Hypohidrotic Ectodermal Dysplasia, Hypohidrotic Ectodermal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
- Interventions
- MK-4002
- Drug
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more
- Conditions
- Childhood Obesity
- Interventions
- multi-component/setting parent-targeted intervention
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 2 Years to 4 Years
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- BrainHQ cognitive training, BrainHQ control games
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse
- Interventions
- Ixazomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Omar Nadeem, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- LX3305, LX3305 Placebo, Methotrexate
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Peripheral Vascular Disease
- Interventions
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Santa Clara, California
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- BBT002, Placebo
- Drug
- Lead sponsor
- Bambusa Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York
- Conditions
- Bowel Incontinence
- Interventions
- Renew Insert
- Device
- Lead sponsor
- Renew Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Los Gatos, California • San Diego, California • Weston, Florida
- Conditions
- Multiple Myeloma
- Interventions
- CX-4945
- Drug
- Lead sponsor
- Cylene Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Kettering, Ohio • Portland, Oregon • Springfield, Oregon + 3 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphomas, Low-grade NHL and Chronic Lymphocytic Leukemia
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w, MM-302 in combination with trastuzumab and cyclophosphamide
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 5
- States / cities
- San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Continuous glucose monitoring system
- Device
- Lead sponsor
- Senseonics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Escondido, California • Walnut Creek, California • Renton, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Filgrastim, Bortezomib, Carfilzomib, Dexamethasone, Cyclophosphamide, Thalidomide, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri